BioCardia Inc Dossier - Source-backed chat

BioCardia Inc

BCDANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.67

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.02Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $15.4M

Enterprise Value $11.3M

Shares Outstanding 13.3M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BioCardia, Inc. is a clinical-stage regenerative medicine company focused on cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's investment thesis centers on its dual-track regulatory strategy for its lead candidate, CardiAMP Cell Therapy, in Japan and the United States. While recent regulatory alignments with Japan's PMDA and the US FDA provide significant clinical validation, BioCardia faces severe liquidity constraints and ongoing capital-raising requirements that present dilution risks for shareholders. A 'Hold' recommendation is warranted as the company navigates its upcoming Q4 2026 Shonin submission in Japan and works to regain Nasdaq listing compliance by October 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$15.50

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The bear case involves regulatory delays or rejection of the CardiAMP Shonin submission by Japan's PMDA, slow enrollment in the US CardiAMP HF II trial, or failure to regain compliance with Nasdaq's stockholders' equity requirement by the October 7, 2026 deadline, leading to delisting. Severe cash burn without securing strategic partnerships would force highly dilutive equity financing or threaten the company's going concern status.

Base CaseCentral scenario

$15.5055%

Matches the consensus mean

The base case assumes BioCardia successfully submits its Shonin application to Japan's PMDA in Q4 2026 and continues steady enrollment in the US CardiAMP HF II confirmatory trial. The company manages to maintain its Nasdaq listing compliance through its recent capital raises and at-the-market equity programs, though it remains highly dependent on further dilutive or non-dilutive financing to fund operations into 2027.

Bull CaseUpside scenario

$25.0025%

The bull case is driven by a successful and timely Shonin approval of CardiAMP Cell Therapy in Japan, unlocking a commercial market of 20,000 eligible ischemic heart failure patients with a precedent reimbursement rate of $124,000 per procedure. Additionally, securing non-dilutive capital through strategic partnerships or licensing agreements for the Helix delivery system and the allogeneic MSC platform would significantly extend the cash runway and validate the technology.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong regulatory alignment with Japan's PMDA, which confirmed that existing clinical data is likely sufficient to support a Shonin approval submission for CardiAMP Cell Therapy.
FDA confirmation that the ongoing CardiAMP HF II trial is appropriate as a confirmatory study to support a Premarket Approval (PMA) pathway in the United States.
Proprietary, clinically validated delivery infrastructure including the Helix Transendocardial Delivery Catheter, which has been accepted for FDA pre-submission review.

Key Investment Risks

Severe liquidity constraints, with cash and cash equivalents of only $951,000 as of March 31, 2026, necessitating continuous capital raises.
Risk of significant shareholder dilution from equity financing programs, such as the $4.4 million capital raise completed in June 2026.
Nasdaq delisting risk if the company fails to regain compliance with the $2.5 million stockholders' equity requirement by October 7, 2026.

Thesis Invalidation Triggers

Failure to submit the CardiAMP Cell Therapy Shonin application to Japan's PMDA by the end of Q4 2026.
Delisting from the Nasdaq Capital Market due to failure to meet the stockholders' equity requirement by October 7, 2026.
Safety concerns or negative efficacy signals emerging from the ongoing CardiAMP HF II clinical trial.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.